Company Analysis
Sign in

Surrozen, Inc. (SRZN)

Nasdaq: SRZN · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2020
Full chart Alerts Compare
Grade2.7
◀ Past 1.9● Present 2.5▶ Future 3.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

7 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Surrozen, Inc.’s names, not what it holds today.

Patents granted
7
7 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 2 in 2024 and 2 in 2023
Applications published
25
4 of them in 2025
Names they are printed under
3
a subsidiary, its own name
By yearGrantedApplications published
'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology6
Pharmaceuticals1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Surrozen Operating, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
13 published
Surrozen Operating, Inc. a subsidiary
US, as the owner printed on each patent
7 granted
4 published
Surrozen, Inc. its own name
named as the applicant on its applications, in US
0 granted
8 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 11, 202512,466,884Tissue-specific WNT signal enhancing molecules and usesBiotechnologySurrozen Operating, Inc.
May 13, 202512,297,278Wnt surrogate molecules and uses thereofBiotechnologySurrozen Operating, Inc.
Mar 4, 202512,240,876Liver-specific Wnt signal enhancing molecules and uses thereofBiotechnologySurrozen Operating, Inc.
Jun 11, 202412,006,368Anti-frizzled antibodies and methods of useBiotechnologySurrozen Operating, Inc.
Apr 16, 202411,958,891Tissue-specific Wnt signal enhancing molecules and uses thereofPharmaceuticalsSurrozen Operating, Inc.
Oct 3, 202311,773,171WNT surrogate molecules and uses thereofBiotechnologySurrozen Operating, Inc.
Sep 5, 202311,746,150Anti-LRP5/6 antibodies and methods of useBiotechnologySurrozen Operating, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 9, 20252025/0313616MODULATION OF WNT SIGNALLING IN OCULAR DISORDERSPharmaceuticalsSurrozen Operating, Inc.
Jul 10, 20252025/0223368WNT SURROGATE MOLECULES AND USES THEREOFBiotechnologySurrozen Operating, Inc.
May 29, 20252025/0171509LIVER-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOFBiotechnologySurrozen Operating, Inc.
Feb 13, 20252025/0051459WNT-SURROGATE AGENTS AND METHODS FOR LACRIMAL GLAND REGENERATIONBiotechnologySurrozen Operating, Inc.
Nov 28, 20242024/0391991MODULATION OF WNT SIGNALLING IN PULMONARY DISORDERSPharmaceuticalsSurrozen Operating, Inc.
Nov 7, 20242024/0368287ANTI-FRIZZLED ANTIBODIES AND METHODS OF USEBiotechnologySurrozen Operating, Inc.
Aug 22, 20242024/0279303TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOFPharmaceuticalsSurrozen Operating, Inc.
Aug 8, 20242024/0262918FC-MODIFIED WNT SURROGATE MOLECULES AND USES THEREOFPharmaceuticalsSurrozen Operating, Inc.
May 9, 20242024/0150473MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERSBiotechnologySurrozen Operating, Inc.
May 9, 20242024/0150458ANTI-LRP5/6 ANTIBODIES AND METHODS OF USEBiotechnologySurrozen Operating, Inc.
What it applied for, 2024 to 2025: Biotechnology 7 · Pharmaceuticals 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SRZN · research, not advice